Nephro Trial Files Throwback Thursday: Canagliflozin for Kidney Disease and T2DM, DASH Diet for BP, and Darbepoetin Alfa in CKD and T2DM
nephrotrialfiles.substack.com
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Perkovic V et al. NEJM (June 2019) Bottom Line: This double-blind, randomized trial included 4401 patients with type 2 diabetes and albuminuric chronic kidney disease who were assigned to receive either canagliflozin or placebo for a median follow-up of 2.62 years. The primary outcome was a composite of end-stage kidney disease, a doubling of the serum creatinine level, or death from renal or cardiovascular causes. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group. The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke and hospitalization for heart failure. There were no significant differences in rates of amputation or fracture.
Nephro Trial Files Throwback Thursday: Canagliflozin for Kidney Disease and T2DM, DASH Diet for BP, and Darbepoetin Alfa in CKD and T2DM
Nephro Trial Files Throwback Thursday…
Nephro Trial Files Throwback Thursday: Canagliflozin for Kidney Disease and T2DM, DASH Diet for BP, and Darbepoetin Alfa in CKD and T2DM
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Perkovic V et al. NEJM (June 2019) Bottom Line: This double-blind, randomized trial included 4401 patients with type 2 diabetes and albuminuric chronic kidney disease who were assigned to receive either canagliflozin or placebo for a median follow-up of 2.62 years. The primary outcome was a composite of end-stage kidney disease, a doubling of the serum creatinine level, or death from renal or cardiovascular causes. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group. The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke and hospitalization for heart failure. There were no significant differences in rates of amputation or fracture.